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Abstract
Objectives Outpatient antibiotic consumption widely
varies across Europe. The investigation of the causes of
such variation may help to identify interventions that
would improve the efficient use of antibiotics. The aim of
this study was to assess the impact of socioeconomic
determinants and the role played by information about
bacterial resistance.
Methods Comparable data on systemically administered
antibiotics and socioeconomic determinants in 17 Euro-
pean countries were available between 2000 and 2005. We
estimated an ad hoc econometric model by means of a
hybrid log–log functional form and random effects gener-
alised least squares regressions. Lagged values and the
instrumental variable method were applied to address
endogeneity of bacterial resistance and infections. Bacte-
rial resistance was measured by the rate of penicillin non-
susceptible Streptococcus pneumoniae isolates (PNSP) and
methicillin-resistant Staphylococcus aureus (MRSA).
Results The population income, demographic structure,
density of general practitioners and their remuneration
method appeared to be significant determinants of antibi-
otic consumption. Although countries with higher levels of
bacterial resistance exhibited significantly higher levels of
per capita antibiotic use, ceteris paribus, the responsiveness
of antibiotic use to changes in bacterial resistance was
relatively low (0.09–0.18).
Conclusions The study confirms that socioeconomic
factors should be taken into account while explaining dif-
ferences in outpatient antibiotic use across countries. The
impact of supply-side factors and incentives attached to
payment schemes for physicians need to be considered in
government interventions to reduce inequalities and
improve effectiveness in antibiotic utilisation.
Keywords Antibiotic use  Cross-country variations 
Bacterial resistance  Socioeconomic inequalities
Introduction
The market for antibiotics is characterised by multiple
imperfections. Above all, antibiotic use may contribute to
widespread bacterial resistance (Elbasha 2003), which still
represents a challenge to achieving sustainable health for
all by the year 2100 (Butler 2008). Antibiotic resistance
leads to the production of newer and more effective gen-
erations of drugs, thus raising the costs for society
(McGowan 2001).
Although antibiotic prescriptions have slightly
decreased during the 1990s and have been roughly stable in
recent years, prescribing practices still vary widely across
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countries (Elsevier et al. 2007). Mean figures of defined
daily doses per 1,000 inhabitants (DID) for 21 European
countries participating in the European Surveillance of
Antimicrobial Consumption (ESAC) project and able to
provide comparable and reliable data for at least 7 years
between 1997 and 2005 show that France (31.55 DID),
Greece (29.67 DID) and Spain (27.31 DID), amongst
others, exhibit significantly higher values of antibiotic use
than Austria (12.47 DID), Denmark (13.08 DID) and the
Netherlands (10.00 DID) (see Fig. 1).
The investigation of the causes of such variation may
help to identify sources of inefficiency in the use of anti-
biotics. As recommended by the WHO Commission on
Social Determinants of Health, the measurement and the
understanding of the problem of inequalities in health and
health-care utilisation is a crucial one. The literature is rich
in studies on socioeconomic determinants of inequalities in
health and health-care utilisation (Kunst 2009). Neverthe-
less, we are not aware of any multifactorial analyses of
socioeconomic determinants of outpatient antibiotic use at
the European level.
Previous studies on socioeconomic determinants of
antibiotic consumption have rather focused on regional
variations within a country (Matuz et al. 2006). This paper
takes a cross-country perspective and tries to assess whe-
ther the impact of determinants of antibiotic use at the
country level, investigated in previous studies, can be
generalised to the European level. Comparable data on
outpatient antibiotic use and bacterial resistance across
European countries have only recently become available
(Goossens et al. 2005) and the impact of information on
bacterial resistance, together with other factors, has not
been previously investigated.
The knowledge of overall levels of bacterial resistance
within a country is likely to be shared by health-care pro-
viders. In several countries, guidelines on antibiotic
treatment and information on routine tests concerning
bacterial resistance are issued by hospitals or local health
authorities every year or every 2 years. Guidelines are
available to general practitioners in the area. This may
convey the idea that bacterial resistance is an indicator of
the effectiveness of antibiotic treatment. If doctors and
patients are concerned about resistance externalities, higher
levels of bacterial resistance will induce them to use anti-
biotics more carefully. However, if bacterial resistance is
relatively high, increasing rates of antibiotic use may be
required to overcome the reduced effectiveness of antibi-
otics. Although physicians eventually switch to newer
antibiotics, several antibiotic therapies may be prescribed
before finding the effective one. Consequently, doctors
may prescribe antibiotics in accordance with existing
information, but the future (social) costs of bacterial
resistance may be underestimated.
This study proposes an econometric model to investigate
the determinants of outpatient antibiotic use in Europe.
Since the interaction between socioeconomic determinants
of consumption and information on bacterial resistance is
simultaneously taken into account and the impact of each
single determinant is assessed, we argue that the approach
can provide an indirect assessment of the effectiveness of
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Fig. 1 Outpatient antibiotic use
in Europe by country and year
[in DID = defined daily doses
(DDD) per 1,000 inhabitants per
day]. Data source: European
Surveillance of Antimicrobial
Consumption, Antwerp, projects
ESAC-1 (2001–2004) and
ESAC-2 (2004–2007)
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policies implemented across Europe between 2000 and
2005 to control antibiotic use and, consequently, to reduce
the social impact of endogenous bacterial resistance.
Methods
Our approach for the investigation of determinants of
antibiotic use in Europe consisted of specifying an econo-
metric model using a set of covariates suggested by
literature. This method was applied, for instance, by Di
Matteo (2005) to investigate the macro-determinants of
health expenditure in the USA and Canada. Multiple
regression models were also recently employed to explore
the association between socioeconomic factors and health-
related aspects, such as the prevalence of substance use
(_Ilhan et al. 2009) and the use of antibiotics within countries
(Filippini et al. 2009a). Amongst determinants of antibiotic
use, literature has underlined the patient education level,
expectations of physicians and patients, cultural aspects,
regulatory practice, and antibiotic price (Belongia and
Schwartz 1998; Cockburn and Pit 1997; Finch et al. 2004).
We defined a consumption function for outpatient anti-
biotic use in Europe, which depended on the health status
of the individuals, patients’ attitudes towards the use of
drugs, antibiotic price and the characteristics of health-care
supply, such as physician density, physicians’ remunera-
tion scheme and information on the level of bacterial
resistance. Socioeconomic variables, such as income and
education, were considered in the model as proxies for the
individual’s stock of health, together with mortality for
infectious diseases, which is difficult to measure.
Researchers generally suggest that the educational level is
a stable indicator of socioeconomic status across age and
over time and may reflect individual’s opportunities better
than income (Hoogendijk et al. 2008). Therefore, our
model served as a reduced form that considered both
demand and supply factors.
The country represented the unit of our analysis. The per
capita consumption of outpatient antibiotics was specified
by the following parsimonious model:
DIDit ¼ f ðYit; DPHit; POPjit; EDUit; EMPWit; REGhi;
PGPkit; Pit; DCOPit; INFit; RESitÞ ð1Þ
where DIDit is the per capita antibiotic use in country i and
year t, as measured by the defined daily doses per 1,000
inhabitants collected by the European Surveillance of
Antimicrobial Consumption. The standard dose is defined
by the World Health Organization. Data were available for
21 European countries between 1997 and 2005. These data
were reliable and exhibited a good degree of comparability,
since the ESAC network screened for detection of bias in
sample and census data, bias by over-the-counter sales
and parallel trade, errors in assigning medicinal product
packages to the Anatomical Therapeutic Chemical Classi-
fication (ATC), and errors in calculations of defined daily
doses (Vander Stichele et al. 2004).
In Eq. 1, Yit is the per capita national income, DPHit is
the physician density, POP1it.. POP5it indicate the per-
centage of the population below 14, between 15 and 24, 25
and 64, 65 and 79, and over 80 years. EDUit is the per-
centage of individuals (25–64 years) with at least upper
secondary education. Cultural aspects that may influence
antibiotic use were obtained by considering women par-
ticipation in the labour market (EMPWit). A geographical
dummy variable (REGhi) that takes into account similari-
ties with adjacent countries was also included. We divided
countries into four groups: ‘‘north’’ (REGni = 1), ‘‘south’’
(REGsi = 1), ‘‘east’’ (REGei = 1), and ‘‘west’’, i.e. the
reference group. The choice of the reference group does
not have an effect on the model. The ‘‘west’’ group
includes countries at the centre of Europe (Austria,
Luxemburg, The Netherlands, Belgium, Germany and
France) and the impact of the other three groups was
measured relative to the comparison group.
We considered three main schemes of remuneration for
general practitioners: fee for service, capitation and salary
(Donaldson et al. 2004). We classified countries according
to these schemes. Two dummy variables, PGP1it and
PGP2it, were introduced to capture the type of remunera-
tion. If doctors were paid a fee per service, then PGP1it was
equal to 1. Conversely, if doctors worked under a salary
regime, then PGP2it was 1. Finally, when both variables
were 0, the country used a capitation scheme. As a con-
sequence, we interpreted the coefficient of PGP1it as the
effect of a fee-for-service remuneration scheme, and the
coefficient of PGP2it as the impact of a salary scheme.
Pit is the price level for a defined daily dose of antibi-
otics. In several countries, insured patients offset some of
the cost of care with copayments. Low copayments are
intended to discourage individuals from using antibiotics
unless when necessary. To capture the effect of copayment,
we introduced a dummy variable (COPit). Full out-of-
pocket COPit was equal to 1. Conversely, when patients
were fully or partially reimbursed, COPit was 0.
Finally, INFit and RESit capture the impact of infections
and the rate of bacterial resistance. We used mortality rates
for infectious diseases as a proxy for the incidence of
bacterial infections, since other indicators were less
exhaustive and less reliable. One can see the level of
bacterial resistance generated by antibiotic use as an
additional economic cost of treatment for the whole com-
munity, since it reduces antibiotic effectiveness. Since the
impact of infectious diseases and bacterial resistance may
be endogenous (Thomas 1987), the estimation procedure of
Eq. 1 addressed this problem, as it will be explained later.
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Regional and national policies towards antibiotics may
also impact on consumption, but standard doses are unli-
kely to be affected. Unfortunately, comprehensive and
reliable data on policies for the whole period 1997–2005
and for all our countries were not available. We assumed
that the influence of policies could be neglected or the
impact of policies was similar across countries over the
observed period. The characteristics of national and
regional campaigns in high-income countries were not
identified and reviewed until very recently (Huttner et al.
2010). There was evidence that campaigns that were for-
mally evaluated had an impact on antibiotic use.
The estimation of Eq. 1 required the specification of a
functional form. Several alternative forms could be con-
sidered, since the theory (Thomas 1987) was quite
ambiguous regarding this issue. Generally, the log–log
specification offers an appropriate functional form for
investigating the responsiveness of antibiotic use to chan-
ges in explanatory variables. The major advantage is that
the estimated coefficients can be interpreted as elasticities,
which are, therefore, assumed to be constant. Conse-
quently, coefficients represent the percentage change in the
value of the explained variable corresponding to a 1%
variation in the value of the explanatory variable. However,
the log transformation was not applied to dummy variables.
Thus, we used a hybrid log–log functional form. Equa-
tion 1 was then specified as follows:
lnDIDit ¼ b0 þ b1 ln Yit þ b2 ln DPHit þ
X6
j¼3
bj ln POPjit
þ b7 ln EDUit þ b8 ln EMPWit þ
X11
k¼9
bkREGki
þ
X13
h¼12
bhPGPhit þ b14 ln Pit þ
X16
l¼15
blDCOPlit
þ b17 ln INFit þ b18 ln RESit þ vi þ eit; ð2Þ
where ln() is a natural logarithm applied to the variable and
mi and eit are error terms with standard distribution
assumptions.
Although data on antibiotic consumption were available
for 21 European countries over 9 years, information on
mortality for infectious diseases, bacterial resistance and
price of pharmaceuticals was available for 17 countries
only (Belgium, Greece, Poland and Slovakia were drop-
ped). Moreover, information was not available for all the
years. The final data set was an unbalanced panel data set
with 81 observations. It is worth noticing that in one of the
three models proposed (Model 2), we gained two obser-
vations since data on mortality rates improved information
available for some countries in 2005. Regressions were
performed by means of the statistical software STATA
(version SE 10.1).
With regard to the choice of the econometric technique,
it should be noted that in the econometric literature we can
find various types of models focusing on cross-sectional
variations over time, i.e. heterogeneity across units and
periods. The most widely used approaches are the fixed-
effects model and the random-effects model. For a detailed
presentation of the econometric methods used to analyse
panel data, see Greene (2003) and Baltagi (2005).
To choose the econometric approach, it was important to
consider that our data set was a panel characterised by a
relatively small number of time periods as well as rela-
tively small number of cross-sectional units. Moreover, the
within variation of the majority of the variables included in
the model was relatively low. In this case, as suggested by
Cameron and Trivedi (2005), the use of the fixed-effects
model could imply a low statistical efficiency of the esti-
mated parameters. Therefore, we focused on random-
effects generalised least squares regressions (Model 1).
However, since bacterial infections and resistance are
plausibly endogenous (Thomas 1987), the estimation of
Eq. 2 may lead to biased results. To tackle this problem,
we adopted two alternative approaches: the inclusion of
lagged values (Model 2) and the instrumental variable
method (Model 3). In Model 2, instead of INFit we used
INFit-1 (the lagged mortality rate for infectious diseases),
and instead of RESit we used RESit-1 (the lagged rate of
bacterial resistance).
For the instrumental variables approach, we considered
some variables related to the spread process of infections.
The density of the population and the size of a country may
plausibly contribute to the spread of infections. Levels of
bacterial resistance may be related to the extensive use of
antibiotics in agriculture and animal breeding. As an
example, Campylobacter is the most frequently reported
zoonotic pathogen to cause human illnesses, and resistant
bacteria tend to be harboured in the meat produced (Swiss
National Science Foundation 2007). The common practice
of using milk produced during antibiotic treatment for
feeding calves and the meat of pigs causes a marked
selection for resistant bacterial strains (i.e. enterococci),
which may enter the food chain. Thus, we specified a
model (Model 3) by instrumenting the rate of bacterial
resistance and the mortality from infectious diseases with
the production of milk and meat of pigs, the use of fertil-
isers in agriculture, the density of the population and the
country area. In this case, a two-stage least squares tech-
nique with random effects was applied.
The annual data available on the determinants of
outpatient antibiotic use between 1997 and 2005 are
summarised in Table 1. These include socioeconomic
characteristics of the population (income, demographic
structure, education and participation in labour market, and
regional clusters), supply-side factors (density of doctors
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and the system of remuneration), incidence of bacterial
infections (mortality rates), price and copayments, and
levels of bacterial resistance.
Data were obtained from a variety of sources. Infor-
mation on per capita income (measured in US dollars in
purchasing power parity), density of physicians, the level
of education and the incidence of infections were extracted
from publications by the OECD (2007). The demographic
structure of the population was derived from Eurostat
tables (Eurostat 2007). From the yearly country profiles
published by the European Observatory on Health Systems
and Policies (2007), we collected information on the main
type of payment system on hold for general practitioners
(fee for service, capitation and salary).
We derived price levels for antibiotics during 2000–
2005 by combining information from two indicators: the
comparative price level index (PLI) and the harmonised
annual average price index (HICP) for pharmaceutical
products. The PLI indicates the price level of each country
compared to the average price level of the 25 EU countries
in 2005. The HICP includes information on price trends for
pharmaceuticals for each country during 2000 and 2005,
where 2005 = 100. These indices are provided by Eurostat
(2007).
For the levels of bacterial resistance, data were obtained
from the European Surveillance on Antimicrobial Resis-
tance (EARSS) database (European Antimicrobial Res-
istance Surveillance System 2007). Routine antimicrobial
Table 1 Variables notation and summary statistics
Description Variables Mean SD Minimum Maximum
Outpatient antibiotic consumption DDDs per 1,000 inhabitants per day (DID) 20.30 6.18 9.75 34.72
Income per capita GDP in PPP/population (Y) 25,926 9,747 8,898 70,600
Antibiotic price Comparative price levels for
pharmaceutical products (P)
93.29 23.75 36.65 160.00
Demographic structure of population Population under 14/population (POP1) 17.90 2.27 14.10 24.00
Population 15–24/population (POP2) 13.41 1.89 10.40 17.50
Population 25–64/population (POP3) 53.67 1.94 47.90 57.70
Population 65–79/population (POP4) 11.53 1.49 8.50 14.70
Population over 80/population (POP5) 3.45 0.80 1.80 5.40
Attainment of high education Population with upper secondary
education/total population (EDU)
66.18 16.91 17.80 89.90
Women participation in the labour market Women employement rate (EMPW) 56.39 12.58 15.99 81.20
Density of doctors Practices/1,000 inhabitants (DPH) 3.14 0.61 1.90 4.90
Bacterial resistance Number of PNSP isolates/tested isolates (RES) 11.25 10.99 0.00 48.00
Number of MRSA isolates/tested isolates (RES1) 18.78 15.95 0.20 50.00
Infections Mortality rate for infectious diseases (INF) 6.70 3.64 2.00 20.10
Population density Population/km2 130.34 98.89 2.62 392.64
Country area Km2 203,068 170,135 2,586 551,500
Animal production Tons of cow’s milk/1,000 7,091.39 7,801.24 113.00 28,723.90
Number of pigs/1,000 7,045.43 7,615.61 3.51 26,989.10
Use of fertilisers Tons/1,000 919,186 1,115,849 15,852 4,988,800
Number of countries
GPs reimbursement Fee for service (PGP1 = 1) 4 (1997–2000) 5 (2001–2005)
Salary (PGP2 = 1) 7 (1997–2000) 6 (2001–2005)
Capitation 10
Copayment Full/partial reimbursement 17
Full out of pocket (DCOP = 1) 4
Regional clusters West 6
East (REGe = 1) 4
North (REGn = 1) 7
South (REGs = 1) 4
Data sources: ESAC, EARSS, OECD, Eurostat, and European Observatory of Health Systems and Policies
DDD defined daily doses, DID defined daily doses per 1,000 inhabitants per day, GDP gross domestic product, PPP purchasing power parity,
PNSP penicillin non-susceptible Streptococcus pneumoniae, MRSA methicillin-resistant Staphylococcus aureus
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susceptibility tests on invasive isolates of Streptococcus
pneumoniae and Staphylococcus aureus are collected by
participating laboratories in each country and submitted to
EARSS. We neglected possible bias in the comparison of
susceptibility data between countries that may be due to
differences in case mix and hospital specialties, or intro-
duced as a result of different laboratory routines between
countries. The time span of the analysis was short because
the data on bacterial resistance were available only after
the systematic collection of bacterial resistance across
European countries started recently (from 1999/2000).
Finally, information on instruments for infections and
bacterial resistance (production of milk and meat of pigs,
use of fertilisers, population density and country area) were
obtained from Eurostat statistics (Eurostat 2007). This
information was supplemented with data directly drawn
from national statistics.
Results
The parameter estimates of the three models are summa-
rised in Table 2. The results were stable and no structural
difference was observed across the models. The time trend
(t) did not show any significant increase in the use of
outpatient antibiotics per capita over time.
The responsiveness of the per capita outpatient antibi-
otic use to a 1% change in the average national income,
ceteris paribus, was between 0.49 and 0.77%.
The level of education reduced antimicrobial con-
sumption significantly at less than 10% only in Model 2. A
similar impact was observed for women participation in the
labour market. In Model 1 and 2, a 1% increase in women
participation reduced antibiotic consumption by 0.57 and
0.67%.
The effect of regional covariates was unclear. Generally,
the coefficients were not significant with the exception of
the northern region.
As for demographic covariates, we observed an associ-
ation between the proportion of individuals aged 14–
25 years and increasing levels of antimicrobial consump-
tion. The impact of individuals below 14 years was also
positive, although not highly significant. Finally, we found
a significant association between the proportion of the
population aged 65–79 years and increasing antimicrobial
use in all the three models.
The physician density had a positive and significant
effect in all three estimations. A 1% increase in physician
density was associated with an increase in antibiotic use
between 0.52 and 0.86%. Covariates PGP1 and PGP2
associated with payment schemes for physicians were also
significant in Model 1 and 2. The coefficients of these
regressors indicated that the fee-for-service remuneration
and the salary remuneration were related to higher levels
of antibiotic use per capita compared to the capitation
reimbursement.
The effect of antibiotic price was captured by means of
two covariates: the price of a daily dose and patient
copayment. We found that price elasticity exhibited the
expected negative sign in all the three models, but only in
Model 3 it was significant at less than 10%. Consequently,
price was associated with a lower antimicrobial consump-
tion. Also, the impact of copayment had the expected
negative sign. This means that purchasing antibiotics out of
pocket instead of under total or partial reimbursement was
associated with lower antimicrobial consumption.
Individual’s health status measured by the mortality rate
for infectious diseases was not significant in any of the
regressions. Conversely, the association between antibiotic
use and bacterial resistance measured by the proportion of
penicillin non-susceptible Streptococcus pneumoniae iso-
lates (PNSP) was positive and highly significant in all the
three model specifications. A 1% increase in the level of
bacterial resistance induced an increase in antibiotic con-
sumption between 0.09 and 0.18%. The higher values of
estimated elasticities were obtained when endogeneity of
bacterial resistance was taken into account. Very similar
results were found in additional regressions using the
methicillin-resistant Staphylococcus aureus (MRSA) indi-
cator instead of PNSP.
Discussion
The investigation of socioeconomic determinants of anti-
biotic use may contribute to the discussion on effective
government interventions to induce efficient use of drugs.
Using an econometric approach, we showed that differ-
ences in outpatient antibiotic use across countries can
hardly be explained by epidemiological, demographic and
cultural factors only. Supply-side factors appear to play an
important role. Indeed, higher levels of antibiotic use per
capita were associated with higher density of doctors and a
fee-for-service remuneration scheme.
The impact of income suggests that richer countries in
Europe use more outpatient antibiotics compared to coun-
tries with lower ability to pay. The result conjectures that
antimicrobials are normal goods. This means that income
may contribute to greater access to medical care. Many
studies have emphasised the role of income in explaining
inequalities in health, health-care and preventive care
utilisation. Recent evidence indicated, for instance, that
income was associated to larger inequalities in the use of
health-care services compared to educational level,
although differences were smaller and less consistent with
regard to primary care (Habicht et al. 2009). As for the use
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of antimicrobials, our income elasticity was lower than the
value observed by Baye et al. (1997) using US data (1.33)
but higher than findings observed by Filippini et al. (2006)
on regional Swiss data (-0.5).
To our knowledge, there are no comparable multivariate
studies on the impact of education on the use of antibiotics.
A comparison with the literature on medical-care utilisation
indicates that antibiotics are quite peculiar. Hunt-McCool
et al. (1994) found positive education elasticity to physician
office visits and hospital care, although the impact was not
very significant. People with low education may perceive
lower utility or higher costs of medical care. Conversely,
more highly educated people may be more informed about
health care and therefore more prone to undergo a treat-
ment. In the case of antibiotics, our result suggests that
educated individuals may restrain from using antibiotics
because they are more concerned about the implications of
bacterial resistance compared to other individuals.
Table 2 Parameter estimates for the three models of outpatient antibiotic use in Europe
Model 1 Model 2 Model 3
Random-effects GLS Random-effects GLS Random-effects 2SLS
Obs. 81 Obs. 83 Obs. 81
Wald v2 (18) 577.06d Wald v2 (18) 651.25d Wald v2 (17) 489.91d
R2 (overall) 0.9030 R2 (overall) 0.9105 R2 (overall) 0.8854
Variables Coeff. Std. Err. Coeff. Std. Err. Coeff. Std. Err.
Constant -9.013965b 4.147910 -7.711871a 3.938099 -10.601980b 4.586670
Y 0.493317c 0.169266 0.537290d 0.126512 0.768270d 0.210580
POP1 1.034719
a 0.587203 0.474416 0.361204 0.309970 0.695105
POP2 1.019814
c 0.338523 1.332917d 0.296425 0.813798b 0.377604
POP4 2.059900
d 0.501518 1.731337d 0.447270 1.684739c 0.568016
POP5 -0.580178
b 0.254358 -0.221079 0.233545 -0.702093b 0.285032
EDU -0.102868 0.207496 -0.335113b 0.170047 0.010325 0.232368
EMPW -0.568037b 0.276119 -0.671807b 0.278283 -0.086852 0.349315
REGe -0.029618 0.156117 0.152904 0.130563 0.065643 0.174499
REGn 0.250409
b 0.111997 0.216708b 0.088739 0.411544c 0.136410
REGs 0.013515 0.231403 -0.173561 0.190079 0.065756 0.256627
DPH 0.587096c 0.209351 0.519010c 0.178472 0.863128c 0.250119
PGP1 0.265965
d 0.065966 0.310308d 0.056701 0.123090 0.089420
PGP2 0.197289
c 0.062775 0.237605d 0.059472 0.075278 0.082179
Pt -0.281583 0.198971 -0.045545 0.167865 -0.391798
a 0.221178
DCOP -0.065513 0.065616 -0.045444 0.057407 -0.121759 -0.074834
INFt -0.001800 0.057033 – – 0.119956 0.081094
INFt-1 – – -0.079473 0.049525 – –
RESt 0.092181
c 0.026898 – – 0.181727d 0.044038
RESt-1 – – 0.088619
d 0.022522 – –
t 0.002920 0.017395 -0.007144 0.012309 -0.028560 0.022243
rk 0 0 0
r 0.041464 0.063106 0.107441
q 0 0 0
GLS generalised least squares, 2SLS two-stages least squares, Y income per capita, POP1 population under 14 years, POP2 population at
15–24 years, POP4 population at 65–79 years, POP5 population over 80 years, EDU attainment of high education, EMPW women participation
in the labour market, REGe western Europe, REGn northern Europe, REGs southern Europe, DPH density of doctors, PGP1 fee-for-service GPs
reimbursement, PGP2 salary-based GPs remuneration, Pt antibiotic price, DCOP no patient copayment (full out of pocket), INFt mortality due to
infectious diseases, INFt-1 mortality due to infectious diseases lagged 1 year, RESt bacterial resistance, RESt-1 bacterial resistance lagged
1 year, t time trend
rk standard deviation of common residuals, re standard deviation of unique (individual) residuals, q variance not explained by differences across
entities
a Significant at 10%, bsignificant at 5%, csignificant at 1%, dsignificant at 0.1%
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Evidence on the effect of women participation in the
labour market suggests similar conclusions. On one hand,
women participating in the labour market are likely to face
high opportunity cost of time and, consequently, may be
inclined to use antibiotics more frequently than other
women. On the other hand, women participating in the
labour market may be more informed and more keen on
using antibiotics carefully. In general, evidence on the role
played by occupational aspects in affecting health behav-
iour across countries remains weak. For instance, strong
association was recently found between parental occupa-
tion and vegetable consumption and TV viewing amongst
adolescents, whereas no association was found between
parental occupation and tobacco and alcohol use amongst
adolescents (Richter et al. 2009).
Regional covariates in our models do not seem to
explain differences in antibiotic use across Europe when
socioeconomic determinants are taken into account. We
found only weak evidence that northern regions use more
antibiotics than western regions, ceteris paribus. Although,
on average, antibiotic use between 2000 and 2005 was
lower in northern Europe (16.98 DID vs. 19.39 DID), the
northern covariate suggests that this was mainly explained
by differences in socioeconomic aspects.
The literature on determinants of health-care expendi-
ture generally suggests that the increasing prevalence of
chronic health problems as people grow older may deter-
mine an increase in the utilisation of health-care services.
The positive and significant effect of the proportion of the
population between 65 and 79 found in our regressions
seems to support this hypothesis. Di Matteo and Grooten-
dorst (2002) also observed a slightly significant increase in
drug expenditure in the population between 64 and 74,
although the result was not confirmed by the more recent
study by Di Matteo (2005). Moreover, because of major
health problems, individuals in the last few years of life
may be more likely to consume antibiotics in nursing
homes or hospital clinics rather than get them prescribed in
outpatient care. Indeed, we observed that individuals older
than 80 years seemed to reduce their per capita consump-
tion of outpatient antibiotics.
The positive effect of physician density might put for-
ward some evidence of supply-induced demand. Moreover,
we found evidence on the impact of payment schemes for
physicians, which is in accordance with the hypothesis on
financial incentives generated by these schemes. Under fee-
for-service remuneration, doctors’ revenue is usually rela-
ted to the number and the time of consultations. This may
imply a positive relationship with the amount of prescrip-
tions, though not straightforwardly. Doctors may then be
prone to meet patients’ preferences for antibiotic treatment
since the risk of losing disappointed patients immediately
after a consultation is higher compared to the capitation
scheme. Conversely, under a capitation scheme, doctors
may have less incentive to prescribe antibiotics. This is
because the quality of treatment is not directly related to
the quantity of antibiotics prescribed, but may improve
with doctor’s ability to induce patient’s compliance and to
reduce inappropriate antibiotic use. Similarly to the fee for
service, salaried practitioners may lack incentives to
restrain from prescribing antibiotics.
Generally, antibiotics are perceived as necessary in the
case of presumed bacterial infections. Since antibiotics are
purchased under doctor’s prescription, their demand may
not be very elastic to the price, as suggested by our esti-
mations. Clearly, this depends on the share of price borne
directly by the patient. Nevertheless, low levels of copay-
ments may not be very successful in discouraging
individuals from using antibiotics if these are perceived as
necessary. Looking at prices for anti-infectives, Baye et al.
(1997) found negative compensated (-0.785) and uncom-
pensated (-0.916) own-price effects. Focusing on the
demand for one antibiotic class, the cephalosporins, Ellison
et al. (1996) calculated own-price elasticities for different
brand/generic names unconditional of drug expenditure
using US wholesale data from 1985 to 1991. Their esti-
mates ranging from -0.38 to -4.34 and were close to our
result (-0.39 in Model 3). The fact that the impact of
copayments was not significant in our regressions may
suggest that individuals were not very responsive to
changes in the cost of drugs, since these may be perceived
as necessary under uncertainty of the nature of infections.
The coefficients of the rate of mortality suggest that
outpatient antibiotic expenditure is not very elastic to the
impact of epidemiological factors. Note, however, that
seasonal epidemic effects are not considered since we
focused on annual consumption of antibiotics. We obtained
similar results by using mortality for pneumonia and
influenza instead of mortality for infectious diseases. Data
available for the former variable were fewer and reduced
the number of observations in our estimations. Looking at
the pharmaceutical consumption for cardiovascular disease
and stroke, Dickson and Jacobzone (2003) found that drug
use was strongly related to indicators of the burden of
disease only for more effective and inexpensive types of
drugs.
The role of bacterial resistance might be underestimated
by Models 1 and 2 if resistance was endogenous. Tests for
endogeneity such as the Durbin test and the Wu-Hausman
test suggested that we could not easily reject the hypothesis
that all covariates were exogenous. Consequently, from a
statistical point of view the results in Model 3 cannot be
preferred to those obtained in Model 1 and 2. However, the
link between bacterial resistance and aspects such as meat
production, the use of fertilisers in agriculture and the
density of the population was generally hypothesised in
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literature. Since correlation between these potential deter-
minants of bacterial resistance and antibiotic use was very
weak, it was straightforward to propose a model specifi-
cation (Model 3) that could strengthen our results.
One possible limitation of our approach is the lack of
general indicators for bacterial resistance and the conse-
quent use of specific indicators such as PNSP and MRSA.
Clearly, these indicators can only be partially associated
with total antibiotic use, but yet represents valid informa-
tion for the overall magnitude of bacterial resistance in a
country.
Increasing levels of bacterial resistance represent a
harmful challenge for the society (Rudholm 2002). Several
studies showed that changes in antimicrobial use may be
followed by changes in antimicrobial resistance (Bergman
et al. 2004; Stephenson 1996). Moreover, bacterial resis-
tance may result in (1) an increased antibiotic use of the
more recently available antibiotics (such as the later fluo-
roquinolones) and/or (2) an increased dosage of the old
classes of antibiotics to overcome resistance against these
antibiotics (such as amoxicillin and amoxicillin/clavulanic
acid) (Austin et al. 1999; Albrich et al. 2004; Filippini et al.
2009b; Woodhead et al. 2005). The former effect may have
a minor impact on the volume of use if it reflects the
substitution of old by new antibiotics only. The latter may
result in a substantial increase of the number of doses. In
both cases, the number of doses may increase through the
number of prescriptions if there are more treatment failures
associated with resistance and the need for retreatment,
possibly with increased dosage or alternative antibiotics.
The purpose of reducing the future social costs of poor
antibiotic effectiveness could also lead to a decrease in the
use of antibiotics. Nevertheless, it is not possible to say
whether or not awareness of resistance by doctors, patients
and policy makers would result in lower rates of antibiotic
use. This is because antibiotic treatment with existing
information may still be the best possible solution for the
patient even though it produces disappointing results in
terms of bacterial resistance.
We estimated that bacterial resistance has a positive and
significant impact on the number of antimicrobial admin-
istrations, although the responsiveness is relatively low.
The effects of public campaigns for promoting careful use
of antibiotics in outpatients were not directly included in
our models. Recently, Huttner et al. (2010) found some
evidence that public campaigns reduced antibiotic use, but
their effects on bacterial resistance could not be accurately
assessed. The relatively low responsiveness of antibiotic
use to increasing levels of bacterial resistance found in our
models could then suggest that public campaigns have
partially mitigated the impact of bacterial resistance on
antibiotic consumption in recent years. Further research
would help to disentangle this relationship.
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